Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

7 years ago
R&D
Biotech Voices

At­las wraps Arteaus sto­ry with $260M roy­al­ty sale as Em­gal­i­ty sales inch­es up­ward

7 years ago
Pharma

Mer­ck­'s Keytru­da wins first check­point in­hibitor lung can­cer ap­proval in Chi­na; Puma sells rights to Ner­l­ynx in ...

7 years ago
News Briefing

AACR roundup: Check­point cock­tails score ear­ly suc­cess­es as Roche's triple shows high re­sponse rate in front­line ...

7 years ago
R&D

AACR: Bay Area biotech bets on an­ti­bod­ies armed with im­muno-stim­u­lant to fight check­point-re­sis­tant can­cers

7 years ago
Discovery

Cam­bridge fund rais­es more than $196M in the UK's hefti­est 2019 fund­ing round

7 years ago
Financing

Pfiz­er biotech spin­out nabs $125M megaround as Bain-backed syn­di­cate bets on its late-stage game plan

7 years ago
Financing
Startups

AACR: Lit­tle Apex­i­gen steals the show with their CD40/Op­di­vo cock­tail as AACR gets un­der­way

7 years ago
R&D

No­var­tis just signed a $1.6B buy­out pact with a lead play­er in an emerg­ing an­ti-in­flam­ma­to­ry field

7 years ago
Deals

Still hunt­ing a block­buster, Mer­ck KGaA scores a win in the FDA ap­proval col­umn — more than 13 years in the mak­ing

7 years ago
Pharma

Af­ter gain­ing key sup­port for Cel­gene buy­out, Bris­tol-My­ers CEO Caforio emerges as like­ly win­ner in loom­ing ...

7 years ago
Deals

BIO tells SEC: do away with quar­ter­ly re­ports for small biotechs

7 years ago
Pharma

Rare dis­ease gene ther­a­py gains Prime sta­tus; FDA ap­proves first drug for in­flam­ma­to­ry arthri­tis nr-axS­pA

7 years ago
News Briefing

Take­da takes a cau­tious step in­to neu­ro­log­i­cal gene ther­a­py, ink­ing pre­clin­i­cal deal with Stride­Bio

7 years ago
Pharma
Cell/Gene Tx

Cel­gene shares jump as Bris­tol-My­ers gains key sup­port from proxy ad­vis­er for loom­ing buy­out vote

7 years ago
Deals

Blue­bird's one-shot gene ther­a­py for be­ta tha­lassemia of­fi­cial­ly se­cures EMA back­ing — ap­proval ex­pect­ed in the ...

7 years ago
Pharma
Cell/Gene Tx

Sunao Man­abe takes top job at Dai­ichi Sankyo in wake of As­traZeneca deal; CAR-T play­er Celyad pro­motes Fil­ip­po Pet­ti ...

7 years ago
Peer Review

Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

7 years ago
Pharma

Durable, safe and ef­fec­tive long-term kid­ney drug da­ta from Tri­ci­da fu­el block­buster po­ten­tial

7 years ago
R&D

Gilead scores a TKO with PhI­II fil­go­tinib da­ta, but still faces some big bouts — and doubts — ahead

7 years ago
R&D

Amarin takes ap­pli­ca­tion to ex­pand Vas­cepa la­bel to the FDA as M&A chat­ter heats up

7 years ago
Pharma

As­traZeneca CEO So­ri­ot bets up to $7B on a ma­jor league col­lab­o­ra­tion for a game-chang­ing HER2 can­cer drug

7 years ago
Deals

Got­tlieb seeks new com­par­a­tive ap­proval stan­dard for opi­oids

7 years ago
Pharma

First Ab­b­Vie chopped a PhI­II, then they wrote off $4B in book val­ue. Now 178 Stem­cen­trx work­ers are get­ting the ax

7 years ago
R&D
First page Previous page 962963964965966967968 Next page Last page
A service from the Financial Times